Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

New Genetic Test Enables Faster Diagnosis of Rare Diseases

By LabMedica International staff writers
Posted on 28 Nov 2025

Rare disease diagnosis often involves a long and uncertain search for the underlying genetic cause. More...

Traditional testing requires multiple separate analyses, although many patients remain without answers. A new clinical solution now offers a faster, more complete way to uncover hereditary conditions: a single test that maps the entire genome more accurately and captures complex variants that older methods miss.

The test, developed and implemented by Radboud University Medical Center (Nijmegen, Netherlands), in collaboration with Maastricht University Medical Center+ (Maastricht, Netherlands), is based on long-read genome sequencing, which measures DNA in much larger fragments and reconstructs all six billion building blocks with significantly higher completeness than short-read approaches. Radboudumc has now begun large-scale clinical use with 5,000 tests per year, initially targeting hereditary blindness and severe intellectual disabilities.

Study findings show that long-read sequencing increases diagnostic yield by more than ten percent for some rare diseases and can detect structural variations that are difficult to identify with conventional methods. The technique also captures DNA modifications that influence gene activity, offering deeper insight into disease mechanisms. Research suggests that ongoing analysis of these full-length genomes could raise the diagnostic uplift to as high as fifteen percent. Published evidence from genomic technology studies supports its suitability and reliability for routine clinical practice.

The introduction of this test is expected to replace around fifteen separate diagnostics, reduce time to diagnosis, and help uncover new hereditary causes of disease. For families, a definitive diagnosis brings clarity, emotional relief, and improved ability to connect with others facing similar conditions. Clinicians can also better assess future reproductive risk and provide more accurate prognostic information. As long-read sequencing becomes a new clinical standard, hospitals anticipate earlier answers and more comprehensive genetic insights for thousands of patients each year.

“Long read sequencing can replace fifteen other genetic tests in clinical practice, making diagnostics faster and more efficient,” said Professor of Genomic Technologies Alexander Hoischen. “I expect this will become the new standard for genome diagnostics and the only test we’ll perform in the future.”

Related Links:
Radboud University Medical Center
Maastricht University Medical Center+ 


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.